The word “blockbuster” gets thrown around quite a bit when it comes to prescription drugs. But now, the blockbuster status of Invega Sustenna, an injectible antipsychotic drug used to treat schizophrenia and related disorders, is a matter of public record.

In an opinion unsealed this week, U.S. District Judge Claire Cecchi in Newark, New Jersey dubbed the drug a “blockbuster” while finding the sole patent that covers it valid. The judge noted the drug netted sales of $1.7 billion in 2019 alone for Johnson & Johnson subsidiary Janssen. The decision, which comes after a three-week bench trial held completely remotely in October 2020, turns back an attempt by generic maker Teva Pharmaceuticals to launch its own competing product.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]